Increased serum levels of advanced oxidation protein products and glycation end products in subjects exposed to low-dose benzene

International Journal of Hygiene and Environmental Health

Volumn 215, Issue 3, 2012, Pages 389-392

  Spatari, Giovanna ^a   Saitta, Salvatore ^a   Cimino, Francesco ^a   Sapienza, Daniela ^a   Quattrocchi, Paolina ^a   Carrieri, Mariella ^b   Barbaro, Mario ^a   Saija, Antonella ^a   Gangemi, Sebastiano ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CNR   (Italy)

Author keywords

Advanced glycation end products (AGEs); Advanced oxidation protein products (AOPPs); Benzene; GSTM1; GSTT1; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BENZENE; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE; PETROLEUM; PLASMA PROTEIN;

ADULT; ARTICLE; BLOOD; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OCCUPATIONAL EXPOSURE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS;

ADULT; BENZENE; BIOLOGICAL MARKERS; BLOOD PROTEINS; GENOTYPE; GLUTATHIONE TRANSFERASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PETROLEUM; POLYMORPHISM, GENETIC;

EID: 84859217609     PISSN: 14384639     EISSN: 1618131X     Source Type: Journal    
DOI: 10.1016/j.ijheh.2011.11.001     Document Type: Article

References (32)

1. Alves S., Amorim A., Ferreira F., Norton L., Prata M.J. The GSTM1 and GSTT1 genetic polymorphisms and susceptibility to acute lymphoblastic leukemia in children from north Portugal. Leukemia 2002, 100:67-71.
2. Anderson M.M., Requena J.R., Crowley J.R., Thorpe S.R., Heinecke J.W. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 1999, 104:103-113.
3. Anderson M.M., Heinecke J.W. Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 2003, 52:2137-2143.
4. Barreto G., Madureira D., Capani F., Aon-Bertolino L., Saraceno E., Alvarez-Giraldez L.D. The role of catechols and free radicals in benzene toxicity: an oxidative DNA damage pathway. Environ. Mol. Mutagen. 2009, 50:771-780.
5. Bassam B.J., Caetano-Anollés G., Gresshoff P.M. Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal. Biochem. 1991, 196:80-83.
6. Bolufer P., Barragan E., Collado M., Cervera J., Lopez J.-A., Sanz M.A. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk. Res. 2006, 30:1471-1491.
7. Budowle B., Chakraborty R., Giusti A.M., Eisenberg A.J., Allen R.C. Analysis of the variable number of tandem repeat locus D1S80 by the polymerase chain reaction followed by high resolution polyacrylamide gel electrophoresis. Am. J. Hum. Genet. 1991, 48:137-144.
8. de Groot L., Posthumus M.D., Kallenberg C.G., Bijl M. Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur. J. Clin. Invest. 2010, 40:835-842.
9. Dougherty D., Garte S., Barchowsky A., Zmuda J., Taioli E. NQO1, MPO, CYP2E1, GSTT1 and GSTM1 polymorphisms and biological effects of benzene exposure - a literature review. Toxicol. Lett. 2008, 10:7-17.
10. Galbraith D., Gross S.A., Paustenbach D. Benzene and human health: a historical review and appraisal of associations with various diseases. Crit. Rev. Toxicol. 2010, 2:1-46.
11. Goldstein B.D. Benzene as a cause of lymphoproliferative disorders. Chem. Biol. Interact. 2010, 19:147-150.
12. Guo Z.J., Niu H.X., Hou F.F., Zhang L., Fu N., Nagai R., Lu X., Chen B.H., Shan Y.X., Tian J.W., Nagaraj R.H., Xie D., Zhang X. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid. Redox Signal. 2008, 10:1699-1712.
13. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 1995, 30:445-600.
14. Kagan V.E., Yalowich J.C., Borisenko G.G., Tyurina Y.Y., Tyurin V.A., Thampatty P., Fabisiak J.P. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol. Pharmacol. 1999, 56:494-506.
15. Kalousová M., Zima T., Tesar V., Dusilová-Sulková S., Skrha J. Advanced glycoxidation end products in chronic diseases - clinical chemistry and genetic background. Mutat. Res. 2005, 579:37-46.
16. Khalade A., Jaakkola M.S., Pukkala E., Jaakkola J.J. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ. Health 2010, 9:31.
17. Kocak H., Gumuslu S., Sahin E., Ceken K., Gocmen Y.A., Yakupoglu G., Ersoy F.F., Tuncer M. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology 2009, 14:273-280.
18. Lin L.C., Chen W.J., Chiung Y.M., Shih T.S., Liao P.C. Association between GST genetic polymorphism and dose-related production of urinary benzene metabolite markers, trans, trans-muconic acid and S-phenylmercapturic acid. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1460-1469.
19. Lin Y.S., Vermeulen R., Tsai C.H., Waidyanatha S., Lan Q., Rothman N., Smith M.T., Zhang L., Shen M., Li G., Yin S., Kim S., Rappaport S.M. Albumin adducts of electrophilic benzene metabolites in benzene-exposed and control workers. Environ. Health Perspect. 2007, 115:28-34.
20. Marsche G., Frank S., Hrzenjak A., Holzer M., Dirnberger S., Wadsack C., Scharnagl H., Stojakovic T., Heinemann A., Oettl K. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ. Res. 2009, 104:750-757.
21. Miraglia N., Assennato G., Clonfero E., Fustinoni S., Sannolo N. Biologically effective dose biomarkers. G. Ital. Med. Lav. Ergon. 2004, 26:298-301.
22. Monks T.J., Butterworth M., Lau S.S. The fate of benzene-oxide. Chem. Biol. Interact. 2010, 19:201-206.
23. Pavanello S., Simioli P., Lupi S., Gregorio P., Clonfero E. Exposure levels and Cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol. Biomarkers Prev. 2002, 11:998-1003.
24. Pemble S., Schroeder K.R., Spencer S.R., Meyer D.J., Hallier E., Bolt H.M., Ketterer B., Taylor J.B. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 1994, 15:271-276.
25. Pietropaoli D., Tatonem C., D'Alessandro A.M., Monaco A. Possible involvement of advanced glycation end products in periodontal diseases. Int. J. Immunopathol. Pharmacol. 2010, 23:683-691.
26. Piwowar A. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Pol. Merkuriusz Lek. 2010, 28:166-169.
27. Seidegård J., Vorachek W.R., Pero R.W., Pearson W.R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. USA. 1988, 85:7293-7297.
28. Seo K.I., Cho K.H., Park K.C., Youn J.I., Eun H.C., Kim K.T., Park S.C. Change of glutathione S-transferases in the skin by ultraviolet B irradiation. J. Dermatol. Sci. 1996, 13:153-160.
29. Sternberg Z., Ostrow P., Vaughan M., Chichelli T., Munschauer F. AGE-RAGE in multiple sclerosis brain. Immunol. Invest. 2011, 40:197-205.
30. Strange R.C., Lear J.T., Fryer A.A. Polymorphism in glutathione S-transferase loci as a risk factor for common cancers. Arch. Toxicol. Suppl. 1998, 20:419-428.
31. Walsh P.S., Metzger D.A., Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 1991, 10:506-513.
32. Wu L., Ma L., Nicholson L.F., Black P.N. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir. Med. 2011, 105:329-336.